Abiopharma

🔍 French Lisa (Executive)

Company: Keenova Therapeutics plc (NONE)

Report Date: 2026-01-01

Detailed Transactions and Holdings:

• Acquired 6,576 shares of Ordinary Shares (Direct)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 10,376.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,986 shares of Ordinary Shares (Direct)
  Date: 2026-01-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 8,390.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 6,576 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 46,031.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3, F4

Footnotes:

• F1: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.
• F2: The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.
• F3: On February 2, 2024, the Reporting Person was granted 16,413 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 4 below.
• F4: Reflects that the Reporting Person received 8,836 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.
• REMARKS: This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.